Search

Displaying results 41 - 50 of 52 in total
  1. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    The development of ranibizumab first began after [bevacizumab], another anti-VEGF anticancer drug, was discovered to inhibit neovascularization and used in the off-label treatment of neovascular age-related

  2. Drug

    Polyvalent antigen-KLH conjugate vaccine

    go.drugbank.com/drugs/DB17565
    Investigational

    It is under investigation in clinical trial NCT01223235 (Polyvalent Vaccine-klh Conjugate + Opt-821 Given in Combination With Bevacizumab).

  3. Drug

    Luveltamab tazevibulin

    go.drugbank.com/drugs/DB17563
    Investigational

    [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

  4. Indication

    Metastatic Cervical Cancer

    go.drugbank.com/conditions/DBCOND0036674
    Drugs: Bevacizumab · Cemiplimab · Irinotecan · Pembrolizumab · Pemetrexed · Tisotumab vedotin +1 more
  5. Drug

    Trifluridine

    go.drugbank.com/drugs/DB00432
    ApprovedInvestigational

    Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to idoxuridine . It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epitheli...

  6. Drug

    Telisotuzumab adizutecan

    go.drugbank.com/drugs/DB21832
    Investigational

    clinical trial NCT06614192 (A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab

  7. Drug

    Atezolizumab

    go.drugbank.com/drugs/DB11595
    ApprovedInvestigational

    Atezolizumab is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, alveolar soft part sarcoma, muscle invasive bladder cancer and co...

  8. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevent...

  9. Indication

    Metastatic Colorectal Cancer (CRC)

    go.drugbank.com/conditions/DBCOND0134580
    Drugs: Aflibercept · Bevacizumab · Cetuximab · Encorafenib · Fluorouracil · Fruquintinib +12 more
  10. Indication

    Metastatic Breast Cancer

    go.drugbank.com/conditions/DBCOND0030200
    Drugs: Anastrozole · Bevacizumab · Carboplatin · Conjugated estrogens · Docetaxel · Doxorubicin +17 more